Mast Therapeutics Inc (NYSEMKT:MSTX) Releases Update On Strategic Direction

    Mast Therapeutics Inc

    Mast Therapeutics Inc (NYSEMKT:MSTX) a clinical-stage biopharmaceutical firm released an update pertaining its recently reported campaign to assess strategic opportunities. The firm has obtained numerous written hints of interest from privately-held firms, including firms with synergistic clinical-stage medication candidates, and is keenly assessing these opportunities.

    The highlights

    Concurrently, Mast Therapeutics will continue to explore methods to tactically monetize its vepoloxamer resources, including via licensing deals. In parallel with assessing strategic prospects, the firm will continue to advance planned and underway investigator-sponsored clinical trials of its lead asset, ‘AIR001’, for the patients’ treatment with HFpEF.

    Brian M. Culley, the CEO, said that the recently-announced strategic procedure has generated numerous opportunities that would turn transformative for company. The company is expeditiously and diligently assessing these strategic options, which they believe could increase returns for their stockholders. They also remain thrilled about the prospect for AIR001 in HFpEF and anticipate more information from investigator-sponsored trials in 2017.

    A couple of sessions earlier, Nano cap Mast Therapeutics posted gains on average volume in anticipation to its report of encouraging initial results from an open-label Phase II clinical study evaluating product candidate AIR001 for the cure of pulmonary hypertension. The data was released in the Journal of Clinical Investigation.

    Preliminary information from 36 patients obtaining AIR001 showed decline in pulmonary capillary wedge and pulmonary, right atrial pressures. The firm stated the impact were most seen in patients with PH related with heart failure with HFpEF. It directs that this subgroup also represented the largest jump in pulmonary artery compliance.

    The lead candidate ‘AIR001’ was well-tolerated with no considerable safety indications. There was also no considerable decline in peripheral oxygen saturation nor jump in methemoglobin levels close to the stopping standard of 5%. Nitrite is a vasodilator and it is recycled in the body to get nitric oxide. Nitrite-mediated NO widens blood vessels and lessens unwanted cell growth and inflammation.


    Please enter your comment!
    Please enter your name here